Department of Cardiovascular Surgery, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, 20, rue Leblanc, Paris 75015, France University Paris Descartes, Sorbonne Paris Cité, Paris F-75475, France INSERM U970, Hôpital Européen Georges Pompidou, Paris, France
Cell Therapy Unit, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Paris F-75010, France INSERM, CIC de Biothérapies (CBT-501) and U1160, Institut Universitaire d'Hématologie, Hôpital Saint-Louis, Paris 75010, France.
Eur Heart J. 2015 Aug 7;36(30):2011-7. doi: 10.1093/eurheartj/ehv189. Epub 2015 May 19.
Comparative studies suggest that stem cells committed to a cardiac lineage are more effective for improving heart function than those featuring an extra-cardiac phenotype. We have therefore developed a population of human embryonic stem cell (ESC)-derived cardiac progenitor cells.
Undifferentiated human ESCs (I6 line) were amplified and cardiac-committed by exposure to bone morphogenetic protein-2 and a fibroblast growth factor receptor inhibitor. Cells responding to these cardio-instructive cues express the cardiac transcription factor Isl-1 and the stage-specific embryonic antigen SSEA-1 which was then used to purify them by immunomagnetic sorting. The Isl-1(+) SSEA-1(+) cells were then embedded into a fibrin scaffold which was surgically delivered onto the infarct area in a 68-year-old patient suffering from severe heart failure [New York Heart Association [NYHA] functional Class III; left ventricular ejection fraction (LVEF): 26%]. A coronary artery bypass was performed concomitantly in a non-infarcted area. The implanted cells featured a high degree of purity (99% were SSEA-1(+)), had lost the expression of Sox-2 and Nanog, taken as markers for pluripotency, and strongly expressed Isl-1. The intraoperative delivery of the patch was expeditious. The post-operative course was uncomplicated either. After 3 months, the patient is symptomatically improved (NYHA functional Class I; LVEF: 36%) and a new-onset contractility is echocardiographically evident in the previously akinetic cell/patch-treated, non-revascularized area. There have been no complications such as arrhythmias, tumour formation, or immunosuppression-related adverse events.
This observation demonstrates the feasibility of generating a clinical-grade population of human ESC-derived cardiac progenitors and combining it within a tissue-engineered construct. While any conclusion pertaining to efficacy would be meaningless, the patient's functional outcome yet provides an encouraging hint. Beyond this case, the platform that has been set could be useful for generating different ESC-derived lineage-specific progenies.
比较研究表明,与具有心脏外表型的细胞相比,定向分化为心脏谱系的干细胞对于改善心脏功能更为有效。因此,我们开发了一种人胚胎干细胞(ESC)衍生的心脏祖细胞群体。
未分化的人 ESC(I6 系)通过暴露于骨形态发生蛋白-2 和成纤维细胞生长因子受体抑制剂而被扩增并向心脏方向分化。对这些心脏诱导信号有反应的细胞表达心脏转录因子 Isl-1 和阶段特异性胚胎抗原 SSEA-1,然后使用免疫磁珠分选对其进行纯化。Isl-1(+) SSEA-1(+)细胞被嵌入纤维蛋白支架中,然后通过手术将其递送到一位 68 岁患有严重心力衰竭的患者(纽约心脏协会 [NYHA] 功能分级 III;左心室射血分数 [LVEF]:26%)的梗死区域。同时在非梗死区域进行了冠状动脉旁路移植术。植入的细胞具有很高的纯度(99%为 SSEA-1(+)),失去了多能性标志物 Sox-2 和 Nanog 的表达,并强烈表达 Isl-1。贴片的术中递送过程迅速。术后过程也没有并发症。3 个月后,患者症状改善(NYHA 功能分级 I;LVEF:36%),在以前无运动能力的细胞/贴片治疗、未再血管化区域,超声心动图可见新出现的收缩力。没有心律失常、肿瘤形成或与免疫抑制相关的不良反应等并发症。
这项观察结果证明了生成临床级别的人 ESC 衍生心脏祖细胞群体并将其与组织工程构建体结合的可行性。虽然任何关于疗效的结论都是没有意义的,但患者的功能结果仍然提供了一个令人鼓舞的提示。除此之外,所建立的平台对于生成不同的 ESC 衍生谱系特异性祖细胞可能是有用的。